GPRC5D/CD3 bispecific antibody
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GPRC5D/CD3 bispecific antibody, covering 2025-09-22 to 2025-09-22. Get the full timeline:
Most recent: Clinical Trial Update: A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]